All In Biotech

Drug Trial Radar · NCT05753566

Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

Efficacy and Safety of Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer: A Prospective, Multi-centre Study

Last checked: Nov 19, 2026Latest source record: Mar 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Mar 2023

Primary completion

Mar 2027

Study completion Mar 2028

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Jiangsu HengRui Medicine Co., Ltd.
First posted
Mar 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy(ADT) and standard salvage radiation therapy(SRT) or rezvilutamide in combination with ADT in prostate cancer patients with biochemical recurrence of prostate-specific antigen(PSA) persistence after radical prostatectomy(RP).

Conditions

  • Prostate Cancer
  • Biochemical Recurrence

Interventions

  • RezvilutamideDrug

    Specifications of 80 mg; orally, once a day

  • Androgen deprivation therapy (ADT)Drug

    Androgen deprivation therapy (ADT), the ADT used by each subject will be determined by the investigator, and the dose and frequency of administration will be consistent with the prescription information

  • SRTRadiation

    SRT according to standard of care (66.6-72 grays will be delivered to the bed of prostate ,\~50.4 grays to the pelvis if needed)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 2-year biochemical progression-free survivalTime frame: 24 months
  2. 3-year biochemical progression-free survivalTime frame: 36 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, China · Recruiting

  • JiangSu Cancer Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.